InnoCare Pharma (HKG:9969, SHA:688428) recorded a net loss attributable to shareholders of 13.6 million yuan for the third quarter of the year, a Monday filing with the Hong Kong Exchange said.
Loss per share stood at 0.01 yuan for the three months ended Sept. 30.
The biopharmaceutical company's operating revenue for the third quarter was 278.0 million yuan, 73.96% higher than a year ago.
For the nine months ended Sept. 30, the company logged an attributable loss of 275.4 million yuan, a loss per share of 0.16 yuan, and 29.85% higher year-on-year operating revenue of 697.7 million.
The company's shares were up over 6% on Monday's close.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。